These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22008047)

  • 1. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs.
    Peters EJ; Motsinger-Reif A; Havener TM; Everitt L; Hardison NE; Watson VG; Wagner M; Richards KL; Province MA; McLeod HL
    Pharmacogenomics; 2011 Oct; 12(10):1407-15. PubMed ID: 22008047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-Scale Drug Screening in Patient-Derived IDH
    Dao Trong P; Jungwirth G; Yu T; Pusch S; Unterberg A; Herold-Mende C; Warta R
    Cells; 2020 Jun; 9(6):. PubMed ID: 32503220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.
    Wen Y; Gorsic LK; Wheeler HE; Ziliak DM; Huang RS; Dolan ME
    Pharmacogenet Genomics; 2011 Aug; 21(8):476-88. PubMed ID: 21642893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
    Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
    Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide discovery of loci influencing chemotherapy cytotoxicity.
    Watters JW; Kraja A; Meucci MA; Province MA; McLeod HL
    Proc Natl Acad Sci U S A; 2004 Aug; 101(32):11809-14. PubMed ID: 15282376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
    Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cell lines in the investigation of pharmacogenetic loci.
    Zhang W; Dolan ME
    Curr Pharm Des; 2009; 15(32):3782-95. PubMed ID: 19925429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copy number polymorphisms and anticancer pharmacogenomics.
    Gamazon ER; Huang RS; Dolan ME; Cox NJ
    Genome Biol; 2011; 12(5):R46. PubMed ID: 21609475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.
    Vivot A; Boutron I; Béraud-Chaulet G; Zeitoun JD; Ravaud P; Porcher R
    Sci Rep; 2017 Jul; 7(1):6882. PubMed ID: 28761069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
    Jiang DM; Chan KKW; Jang RW; Booth C; Liu G; Amir E; Mason R; Everest L; Elimova E
    Cancer Med; 2019 Apr; 8(4):1584-1593. PubMed ID: 30848108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic analysis of FDA-approved anticancer drugs.
    Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H
    BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
    Chen EY; Raghunathan V; Prasad V
    JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study.
    Etan T; Amir E; Tibau A; Yerushalmi R; Moore A; Shepshelovich D; Goldvaser H
    Cancer Treat Rev; 2020 Dec; 91():102113. PubMed ID: 33128993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
    Marquart J; Chen EY; Prasad V
    JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts.
    Nelson B
    Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.